CervoMed secures US patent for pure DLB drug into 2042

CervoMed Inc., a clinical-stage biotechnology company, has secured a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering its drug candidate neflamapimod. The patent protects the use of neflamapimod for treating dementia with Lewy bodies (DLB) in patients without substantial Alzheimer's disease-like tau pathology, a condition referred to as "pure DLB". This intellectual property protection is expected to extend into 2042, with potential for longer coverage through patent term extensions.

The patent specifically covers the treatment of DLB characterized by the absence of substantial tau pathology, which can be identified via plasma levels of pTau or brain imaging. This protection supports CervoMed's strategy to target patients specifically suffering from pure DLB. Currently, there are no approved treatments for DLB in the United States or the European Union, highlighting the significance of this development for the company's pipeline.

Patent Details

The newly allowed patent provides CervoMed with a strategic advantage in the neurodegenerative disease space. Below are the key details regarding the patent and the drug candidate:

Aspect	Details
Drug Candidate	Neflamapimod
Target Indication	Dementia with Lewy Bodies (Pure DLB)
Patient Criteria	No substantial Alzheimer's disease-like tau pathology
Diagnostic Methods	Plasma levels of pTau or brain imaging
Patent Protection	Expected into 2042
Potential Extension	Patent term extension available

Strategic Context

By securing this patent, CervoMed reinforces its focus on age-related brain disorders. The allowance notice marks a progression in the company's efforts to bring a therapeutic option to a market that currently lacks approved treatments for DLB. The exclusivity granted by the patent is critical for the commercial viability of neflamapimod should it receive regulatory approval.

CervoMed Director Joshua S. Boger acquired a significant stake in the company through a private placement, purchasing 955,414 units at a purchase price of $3.14 per unit. The transaction, completed on June 11, 2026, was executed by the Joshua S. Boger 2021 Trust DTD 12/09/2021, for which Boger serves as the sole trustee. This acquisition increases the director's exposure to the company's equity and derivatives.

Transaction Details

The private placement was conducted pursuant to a securities purchase agreement dated June 9, 2026. Each unit purchased comprises one share of common stock, one Series B warrant, and one Series C warrant. The Series B warrants carry an exercise price of $3.32 per share and are exercisable immediately, expiring five years from issuance. The Series C warrants have an exercise price of $3.14 per share, are also exercisable immediately, and expire one year from issuance.

Component	Exercise Price	Expiry
Series B Warrant	$3.32 per share	5 years
Series C Warrant	$3.14 per share	1 year

Ownership and Limitations

Following the transaction, the Joshua S. Boger 2021 Trust holds 1,600,117 shares of common stock, while The Amy S. Boger 2021 Trust holds 195,748 shares. Boger serves as the sole trustee for both entities but disclaims beneficial ownership of these securities for Section 16 purposes. The warrants include a provision preventing the exercise of any portion that would cause the trust to beneficially own more than 19.99% of the outstanding common stock immediately thereafter.